IDIAPJGol has signed a strategic alliance with the Pan American Health Organization (PAHO) to enhance the detection of post-vaccination adverse events and to promote multinational studies that generate scientific evidence to inform decisions in immunization programs.

On behalf of IDIAPJGol, the initiative is coordinated by researchers Felipe Villalobos and Martín Solorzano.

The agreement has begun with the development of a specific protocol to assess the safety of the dengue vaccine in Brazil. The project places particular emphasis on identifying and monitoring a potential risk of vaccine-associated enhanced disease.

An alliance to generate evidence

This collaboration builds on IDIAPJGol’s track record in international vaccine safety studies, its expertise in active monitoring using real-world data, and its active participation in networks such as VAC4EU and the Global Vaccine Data Network (GVDN).

Through this agreement, PAHO and IDIAPJGol aim to generate solid and internationally comparable evidence that strengthens public trust and supports evidence-based decision-making to improve immunization programs in Latin America and the Caribbean.

Stronger and more equitable surveillance systems

The collaboration also includes the implementation of pilot networks for active surveillance of adverse events in primary care, as well as the creation of training programs in digital pharmacovigilance for professionals from different countries.

These programs will include tools to improve detection, reporting, and analysis of adverse events, with the goal of strengthening national surveillance systems and reducing inequalities in technical capacity.